News

Article

In the Lab eNewsletter

Pharmaceutical Technology's In the Lab eNewsletter, May 2023
Volume18
Issue 5

JMI Laboratories and bioMérieux Enter Antimicrobial Resistance Diagnostics Partnership

Author(s):

JMI Laboratories and bioMérieux will work to improve microbiology diagnostics tools.

JMI Laboratories, a microbiology laboratory owned by Element Materials Technology, and bioMérieux, a French biotechnology company specializing in diagnostics, announced a six-year partnership in an April 20, 2023 press release. The collaboration will aim to improve microbiology diagnostics in tools to fight antimicrobial resistance (AMR).

According to a company press release, Antimicrobial Stewardship Programs are dependent on rapid, reliable testing that must be continuously evaluated against new and emerging strains of global pathogens. In this partnership, bioMérieux will use data collected through JMI’s microbial surveillance tools to continuously assess AMR results.

“We are excited to partner with bioMérieux on these projects as we appreciate their commitment to improving patient care by providing accurate microbial identification and antimicrobial susceptibility testing results,” said Mariana Castanheira, chief scientific officer of JMI Labs, in the press release. “Our scientists look forward to managing these studies testing challenging organisms, including those carrying important mechanisms of resistance.”

“Through our combined efforts, we can proactively alert the scientific community of potential growing threats and effectively steer antimicrobial research and development,” said François Lacoste, executive vice-president, Research & Development, bioMérieux, in the release.

Source: bioMérieux

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
 Benjamin McLeod and Sebastian Lykke Skafte Andersen go behind the headlines to examine the motivations behind recent M&A activity, tariff responses, and more.
Tariffs & Trade Policy: Results of a Bio/Pharma Peer Survey